"Looking back at the last couple of years, it appears that there is a 10-20% drop in revenues (compared to the 3rd) for the final quarter of the year..so there appears to be a seasonal drop. As such, we may only get about a breakeven 4th quarter, or even a slight loss. A breakeven report would leave the full year earnings at around 1.9 million, which is good for about 2.5 cents a share. With the 9 month growth rate of almost 60%, surely this should demand a PE of 15 or more, which would be a price of around 37 cents. A PE of only 10 would be about 25 cents. Hope that helps,"
"BNLB is finally getting some attention, though from the newsletter game players...in any case, SOME will take notice of their highly undervalued status on a fundamental basis. What the company must now do is report their numbers for the whole year to take advantage of the attention. Without those some will remain skeptical that their earnings are real. They need a great year also to get on the radar of folks who focus on full year results.
If the 4th quarter is in line, the stock should be trading over 30 cents easily.."
"Dr Phillip Frost, a billionaire entrepreneur, invested in MusclePharm, which is in the same area of nutritional supplements as BNLB. MSLP's revenues in 2012 are about the same as BNLB's but they have awful earnings. BNLB is more solid fundamentally. MSLP has a market cap of over $30 million. The equivalent for BNLB would be a stock price of 40 cents..
Market Data 
Markets 
